Chfr acts with the p38 stress kinases to block entry to mitosis in mammalian cells

Takahiro Matsusaka and Jonathon Pines
Wellcome/Cancer Research UK Gurdon Institute, and Department of Zoology, University of Cambridge, Cambridge CB2 1QR, England, UK


Introduction
The decision to enter mitosis is not lightly made. There are several distinct checkpoints that prevent mitosis when internal or external conditions are not favorable. The most well-characterized checkpoints are triggered by unreplicated or damaged DNA, which prevent mitosis by pathways dependent on the ATM and ATR protein kinases. These checkpoints block cells from entering mitosis by preventing the Cdc25 phosphatases from activating the cyclin B1-Cdk1 kinase. Cyclin B1-Cdk1 is fully activated at the end of prophase (Jackman et al., 2003), and this, along with nuclear envelope breakdown in metazoans, correlates with irreversible entry into mitosis. Thus, there are grounds to consider the bulk of prophase not as part of mitosis but as the final part of interphase. Moreover, a wide variety of insults in late G2 phase and early prophase will prevent cells from initiating mitosis. Indeed, Bullough and Johnson (1951) coined the term “antephase” to describe the period in late G2 phase, just before the first visible signs of chromosome condensation become evident, during which normal mouse epidermal cells are reversibly delayed when subjected to stresses including radiation damage, hypothermia, fluoride treatment, and lack of microtubule function. Rieder and Cole (1998, 2000) further showed that rat kangaroo, green monkey kidney, and pig kidney cells in early prophase will transiently return to antephase when they are exposed to cold, osmotic shock, or microtubule poisons such as colcemid (for review see Pines and Rieder, 2001; Mikhailov and Rieder, 2002). With the agreement of Conly Rieder we will refer to this as the antephase checkpoint to make clear that this acts at the end of interphase and not in mitosis. This checkpoint is distinct from the DNA damage checkpoint because it does not require ATM or ATR (Rieder and Cole, 2000). It is also weakened or absent in several tumors and transformed cell lines (Rieder and Cole, 1998). The checkpoint is most easily assayed in early prophase, during chromosome condensation, when colcemid treatment is able to cause PtK1 cells in prophase to return to antephase, but only before the nucleoli have broken down. After the nucleoli have disassembled, colcemid is unable to trigger the return to antephase and cells initiate mitosis (Rieder and Cole, 1998). Nucleolar breakdown correlates with the activation and nuclear translocation of cyclin B1-Cdk1 and, therefore, could be considered one of the first signs of entry into mitosis. At present, the mechanisms behind the antephase checkpoint are ill defined.

One protein that has been suggested to be part of the antephase checkpoint is Chfr (checkpoint protein with an FHA domain and ring finger; Scolnick and Halazonetis,
2000), a ubiquitin ligase that is down-regulated in several cell lines through methylation of its promoter (Mizuno et al., 2002). Chfr was originally reported to delay progress to prometaphase in the presence of colcemid (Scolnick and Halazonetis, 2000), and cells were surprisingly described as delaying with high cyclin B1-Cdk1 activity (Scolnick and Halazonetis, 2000), which conflicted with a role as part of the antephase checkpoint because cyclin B1-Cdk1 is fully activated only in late prophase. However, in Xenopus laevis extracts, Chfr is able to delay the activation of cyclin B-Cdk1, apparently by targeting the Polo-like kinase, Plx, for degradation by the proteasome (Kang et al., 2002), thereby preventing the activation of the Cdc25 phosphatase that activates Cdk1. Chfr has also been reported to affect Polo-like kinase levels in human cells in response to DNA damage (Shitivelman, 2003). But whether Chfr does target Polo for degradation or not is debatable because Chfr has been shown to conjugate ubiquitin via its lysine 63 residue (Bothos et al., 2003) that normally acts in signal transduction, especially for stress signals (Deng et al., 2000; Ulrich and Jentsch, 2000; Hofmann and Pickart, 2001; Pickart, 2001; Wang et al., 2001), rather than to target proteins to the proteasome.

The ability of a variety of stress stimuli to delay entry to prophase might implicate the p38 stress-activated kinases as components of the antephase checkpoint. Members of the family of p38 kinases can be activated by a variety of stresses (for review see Nebreda and Porras, 2000), and some have been shown to be able to delay the cell cycle in G1 and in G2 phase (for review see Bulavin et al., 2002). In animal cells, the p38α kinase has been reported to phosphorylate and inactivate the Cdc25B phosphatase in response to UV damage in G2 phase (Bulavin et al., 2001), thus delaying mitosis. p38α has also been reported to be part of the spindle assembly checkpoint that delays cells in mitosis when chromosomes are not properly attached to the spindle (Takenaka et al., 1998). However, until now the stress kinases have not been shown to have a role in the antephase checkpoint.

Here, we have investigated the mechanisms required for the antephase checkpoint in mammalian cells. We show that in response to microtubule poisons the checkpoint requires the Chfr ubiquitin ligase, but not the proteasome, and that Chfr does not delay mitosis by targeting Plk1 for degradation. Rather, we show that the microtubule-dependent antephase checkpoint acts through the p38 kinases.

**Results**

Several transformed cell lines had been shown to lack the antephase checkpoint (Rieder and Cole, 2000), and some of these had also been described as lacking Chfr (Scolnick and Halazonetis, 2000). Therefore, we were intrigued by the possibility that the antephase checkpoint might require Chfr. To investigate this possibility, we established two assays for the antephase checkpoint and compared PtK1 cells, where the checkpoint was originally defined (Rieder and Cole, 1998), with HeLa and U2OS cells that lack the checkpoint (Rieder and Cole, 2000). Chfr is not expressed in HeLa cells (Fig. 1 D) and is mutated in U2OS cells (Scolnick and Halazonetis, 2000). In our primary assay, we identified cells in early to mid-prophase by DIC microscopy using the criterion of discernible chromosome condensation with an intact nucleolus (Fig. 1 A and Video 1, available at http://www.jcb.org/cgi/content/full/jcb.200401139/DC1; Rieder and Cole, 1998) and continually monitored the response of the cells by time-lapse microscopy. When prophase PtK1 cells were treated with nocodazole or colcemid and followed by time-lapse DIC microscopy, they decondensed their chromosomes after a variable period of time and returned to anaphase, which is illustrative of an intact antephase checkpoint (Fig. 1 A and Video 1). These cells remained in anaphase for anywhere between 1 and 6 h (Fig. 1 E) before returning to mitosis (Video 1 and Fig. 1 F). In contrast, HeLa cells and U2OS cells did not return to interphase but continued on into mitosis (Fig. 1, B and C). In agreement with Rieder and Cole’s (1998) original observations, PtK1 cells were unable to return to interphase once the nucleoli began to disassemble, which, from our previous studies on cyclin B1, is the time when cyclin B1 is activated and moves into the nucleus (Furuno et al., 1999; Jackman et al., 2003). To corroborate these results, we used a second assay according to Rieder and Cole (2000). We treated a population of PtK1 cells with nocodazole or colcemid and, at various times after treatment, stained the cells with Hoechst 33342 and determined the proportion of cells at each stage of mitosis by fluorescence microscopy. We confirmed that cells with an intact antephase checkpoint show a marked decrease in the number of cells in prophase after drug treatment (Fig. S1, available at http://www.jcb.org/cgi/content/full/jcb.200401139/DC1).

Chfr is required for the antephase checkpoint triggered by microtubule poisons

To determine if Chfr was required for the antephase checkpoint we generated a dominant-negative mutant by deleting the FHA domain from Chfr (Scolnick and Halazonetis, 2000). When injected into PtK1 cells, the mutant but not the wild-type protein abrogated the antephase checkpoint; early prophase cells no longer returned to interphase after treatment with nocodazole or colcemid but continued on to breakdown their nuclear envelope (Fig. 2 A, Table I, and Video 2, available at http://www.jcb.org/cgi/content/full/jcb.200401139/DC1). Some cells arrested in prophase and were separately scored (Table I). As a more direct test for whether or not Chfr was required for the antephase checkpoint, we generated cell lines in which Chfr was expressed under an inducible promoter (the tet-off system). We used U2OS cells as the parental cell line, as in U2OS cells the endogenous Chfr is inactive due to a point mutation in the carboxyl-terminus (Scolnick and Halazonetis, 2000). We isolated clones of cells that on an immunoblot expressed approximately equivalent levels of wild-type Chfr or Chfr with a mutation in the RING finger to disable its ubiquitylation activity (Fig. 2 B). Immunofluorescence analysis showed that most individual cells expressed similar levels of the proteins (Fig. 2 C), and that at least 50 and 80% of the cells in the population expressed wild-type...
or mutant Chfr, respectively. We found that cells expressing wild-type Chfr were able to return to interphase after challenging with colcemid in early prophase, whereas the uninduced cells and cells expressing the inactive Chfr mutant continued on to mitosis (Fig. 2 D and Videos 3 and 4, available at http://www.jcb.org/cgi/content/full/jcb.200401139/DC1). The cells were fixed and stained after the assays to show that they were expressing the ectopic Chfr protein (Fig. 2 D and Videos 3 and 4). We also synchronized cells expressing wild-type Chfr in S phase, and used time-lapse microscopy to compare their entry into mitosis with and without colcemid treatment in G2 phase. This comparison showed that colcemid delayed mitosis by an average of 3 h in a substantial proportion of the cells (Fig. 2 E). Thus, Chfr is able to restore the microtubule-dependent antephase checkpoint.

The antephase checkpoint requires ubiquitylation but not proteasome activity

Chfr had been reported to ubiquitylate and target for destruction the Polo-like kinase in X. laevis cycling extracts, thereby delaying the activation of cyclin B-CDK1 (Kang et al., 2002). Therefore, we assayed whether or not Plk1 proteolysis was involved in the antephase checkpoint in mammalian somatic cells. However, we were unable to detect any loss of Plk1 upon activation of the antephase checkpoint, either by immunofluorescence analysis (not depicted) or by quantifying the level of a Plk1-GFP fusion protein in living cells (Fig. 3 A). (This Plk1-GFP fusion protein mimics the endogenous protein because it is degraded at the end of mitosis [Lindon and Pines, 2004].) Moreover, we found that the antephase checkpoint did not require proteasome-dependent degradation. Prophase
Although polyubiquitinated proteins are often targeted for destruction by the proteasome, they have also been shown to act as signaling molecules, especially when conjugated via K63. Moreover, Chfr has been characterized as a ubiquitin ligase that requires Ubc13-Mms2 (Bothos et al., 2003), a dimeric ubiquitin-conjugating enzyme that preferentially conjugates ubiquitin through its K63 and not K48 residue. To test whether or not the antephase checkpoint required ubiquitylation, we injected methyl-ubiquitin into cells to block ubiquitylation. This treatment abrogated the antephase checkpoint.

PtK1 cells treated with the specific proteasome inhibitors MG132 or epoxomicin returned to interphase after treatment with nocodazole or colcemid, which is indicative of a functional checkpoint (Table II). In these experiments, MG132 and epoxomicin did block protein degradation because prophase cells treated with these compounds without nocodazole subsequently arrested in metaphase. Thus, mammalian cells appeared to differ from X. laevis extracts where proteasome inhibitors blocked the ability of Chfr to inhibit mitosis (Kang et al., 2002).

Figure 2. Chfr is required for the antephase checkpoint. (A) Fluorescence (top right) and DIC images of PtK1 cell expressing a GFP tagged ΔFHA mutant of Chfr. The cell was treated with 15 μM colcemid at 0 min (top left) and continued on into mitosis (bottom panels). The complete series of DIC images are presented in Quicktime format as Video 2. (B) Anti-Chfr immunoblot of tetracycline-inducible Chfr cell lines. (lane 1) Uninduced cells; (lane 2) cells expressing epitope-tagged wild-type Chfr; (lane 3) cells expressing epitope-tagged RING-finger mutant of Chfr. Epitope-tagged Chfr is marked by the arrowhead, endogenous Chfr is marked by the arrow. Molecular mass markers are indicated on the left. (C) Box plot of the relative fluorescence intensities of individual U2OS cells of the stable cell lines expressing inducible Chfr proteins. Cells were stained with anti-Xpress epitope antibody to detect wild type (wt, n = 15) or the RING finger mutant (RING, n = 16) of Chfr. (D) DIC images of U2OS cell lines expressing an inducible wild type (left) or a RING finger mutant (right) of Chfr were treated with 15 μM colcemid at 0 min (top). Cells expressing wild-type Chfr decondensed their chromosomes and returned to antephase for least 3.5 h (middle left). In contrast, cells expressing mutant Chfr continued on into mitosis (middle right). Cells were then fixed and stained with anti-Xpress tag antibody to assay for expression of the ectopic Chfr (bottom). Bar, 10 μm. The complete series of images are presented in Quicktime format for the cell expressing wild-type Chfr as Video 3 and for the RING finger mutant as Video 4. (E) Colcemid delays mitosis in U2OS cells expressing wild-type Chfr. Synchronized U2OS cells expressing wild-type Chfr from an inducible promoter were treated or not with 15 μM colcemid in G2 phase. Cells were monitored by time-lapse microscopy, and the time at which they broke down their nuclear envelopes was plotted as a frequency histogram. Cells are representative of two separate experiments. Videos are available at http://www.jcb.org/cgi/content/full/jcb.200401139/DC1.
phase checkpoint in 4 out of 8 cells, which carried on into mitosis (3 other cells arrested in prophase), whereas injecting wild-type ubiquitin allowed 8 out of 10 cells to return to interphase when challenged with colcemid (Fig. 3 B and Table II). Thus, the antephase checkpoint appeared to require ubiquitylation but not proteasome-dependent proteolysis.

The p38 stress kinase is required for the antephase checkpoint
Ubiquitylation through K63 has been shown to activate the stress kinase pathway through the TAK1 kinase in response to interleukin-1 (Wang et al., 2001). In addition, cells treated with low doses of anisomycin have a reduced mitotic index (Lindon, C., personal communication). Anisomycin has been shown to be a potent activator of p38 stress kinases (Cano et al., 1994), and p38 kinases can also be activated by treating late G2/mitotic cells with nocodazole (Takenaka et al., 1998). Therefore, we analyzed if the p38 kinases could play a part in the antephase checkpoint. We found that anisomycin was as effective as nocodazole or colcemid in both reducing the number of prophase cells in the population (supplemental material) and causing mid-prophase cells to return to interphase (Fig. 4 A and Video 5, available at http://www.jcb.org/cgi/content/full/jcb.200401139/DC1). Treatment with other stimuli known to activate the p38 stress kinases such as 5 mM H2O2 or 10 j/m2 UV also caused a decline in the number of prophase cells (supplemental material). To support a role for the p38 stress kinases, we compared the effects of the p38α and β kinase inhibitors SB203580 and SB202190, with the inactive compound SB204274 as a control. In both of our assays, SB203580 and SB202190 abrogated the antephase checkpoint induced by colcemid, whereas SB204274 had no effect (Fig. 4 B and supplemental material). In these experiments, cells treated with colcemid subsequently arrested for several hours in

<p>| Table I. Induction of the antephase checkpoint in PtK1 cells |
|-----------------|-----------------|-----------------|</p>
<table>
<thead>
<tr>
<th>Challenge</th>
<th>Return to interphase</th>
<th>Continue to mitosis</th>
<th>Arrest in prophase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cells expressing wild-type Chfr</td>
<td>5</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Colcemid</td>
<td>0</td>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>Anisomycin</td>
<td>5</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Inject p38α</td>
<td>4</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

PtK1 cells expressing wild type or ΔFHA-Chfr were treated as described and their behavior was assayed by time-lapse DIC microscopy. Cells that decondensed their chromosomes were scored as returning to interphase, and cells that broke down their nuclear envelopes were scored as continuing to mitosis.

<p>| Table II. Effect of ubiquitin and the proteasome on the antephase checkpoint |
|-----------------|-----------------|-----------------|</p>
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Return to interphase</th>
<th>Continue to mitosis</th>
<th>Arrest in prophase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ubiquitin</td>
<td>8</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Methyl-ubiquitin</td>
<td>1</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>MG132</td>
<td>12</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Epoxomicin</td>
<td>4</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

PtK1 cells were treated as described and their behavior was assayed by time-lapse DIC microscopy. Cells that decondensed their chromosomes were scored as returning to interphase, and cells that broke down their nuclear envelopes were scored as continuing to mitosis.
prometaphase in the presence or absence of p38 inhibitors, which is indicative of an intact spindle assembly checkpoint.

These results strongly indicated that the p38α and/or β kinases were necessary for the antephase checkpoint. However, although SB203580 and SB202190 had been shown to be highly specific inhibitors of p38 in vitro, they could have acted by inhibiting another, related kinase in vivo. To eliminate this possibility, we injected active p38 kinases into early prophase PtK1 cells and found that either p38α or p38β forced the majority of cells to return to interphase, whereas p38γ did not (Fig. 4 C and Table III). Injecting the related MAP kinase family member, Erk2, had no effect on progression through prophase (Fig. 4 C and Table III). Thus, we concluded that the p38α and β stress kinases were important components of the antephase checkpoint.

To discriminate between whether the p38 kinases lay up or downstream of Chfr, we treated U2OS cells, which have a mutant Chfr, with 50 ng/ml anisomycin for 30 min to activate the p38 stress kinases and followed their entry into mitosis by time-lapse microscopy. Anisomycin blocked the appearance of prophase cells within 30 min and delayed entry to mitosis in the majority of the population by an average of 90 min, indicating that U2OS cells might have some of the components necessary for the antephase checkpoint (Fig. 5 A). However, the decline in mitotic cells might have been caused by cells arresting in late G2 phase, and we wished to determine whether or not anisomycin could cause cells to return from prophase to antephase. Therefore, we monitored the behavior of the centrosomes in HeLa cells expressing α-tubulin-YFP, which normally accumulated on centrosomes in early prophase (Khodjakov and Rieder, 1999; Fig. 5 B and Video 6, available at http://www.jcb.org/cgi/content/full/jcb.200401139/DC1), and found that anisomycin was able to reverse this recruitment (Fig. 5 C and Video 7, available at http://www.jcb.org/cgi/content/full/jcb.200401139/DC1). Thus, even in the absence of a functional Chfr protein, activating the p38 kinases appeared to be able to mediate the antephase checkpoint.

One interpretation of these results was that Chfr was required to activate p38 when cells were treated with nocodazole. To test this interpretation, we abrogated the antephase checkpoint in PtK1 cells by expressing the ΔFHA mutant of Chfr. When challenged with anisomycin or injected with active p38 kinase the cells returned to inter-

<table>
<thead>
<tr>
<th>Protein injected</th>
<th>Return to interphase</th>
<th>Continue to mitosis</th>
<th>Arrest in prophase</th>
</tr>
</thead>
<tbody>
<tr>
<td>GST-p38α</td>
<td>6</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>p38α</td>
<td>6</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>p38β</td>
<td>7</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>p38γ</td>
<td>1</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Cyclin A–CDK2ΔF</td>
<td>0</td>
<td>9</td>
<td>4</td>
</tr>
<tr>
<td>Cyclin A–CDK2</td>
<td>7</td>
<td>4</td>
<td>3</td>
</tr>
</tbody>
</table>

PtK1 cells were injected with the proteins as described and their behavior was assayed by time-lapse DIC microscopy. Cells that decondensed their chromosomes were scored as returning to interphase, and cells that broke down their nuclear envelopes were scored as continuing to mitosis.

Figure 4. **p38 stress kinases are required for the antephase checkpoint.** (A) DIC images of PtK1 cells in early prophase before (left) or after (right) treatment with 50 ng/ml anisomycin. The complete series of images for the cell treated with anisomycin are presented in Quicktime format as Video 5, available at http://www.jcb.org/cgi/content/full/jcb.200401139/DC1. (B) DIC images of PtK1 cells in early prophase that were treated at 0 min with 15 μM colcemid plus 5 μM SB203580 (top), or 15 μM colcemid plus 5 μM SB202474 (bottom) and followed by time-lapse microscopy. Cells with the active p38 inhibitor (SB203580) continued into mitosis. Cells are representative of four cells in two experiments for each SB compound. (C) PtK1 cells in early prophase were injected with active p38α (top) or active ERK2 (bottom) and followed by time-lapse DIC microscopy at 3-min intervals. The cell injected with p38 returned to antephase. Bars, 10 μm.
phase (Fig. 5 D and Table I), indicating that p38 was likely to be downstream of Chfr.

**Active cyclin A–CDK2 kinase can overcome the antephase checkpoint**

Lastly, we considered the possible mechanisms by which the p38 kinases might reverse progress through prophase. We had previously shown that cyclin A–dependent kinase activity was important for cells to enter and progress through prophase (Furuno et al., 1999) and that cyclin B1–Cdk1 kinase was significantly activated only towards the end of prophase (Jackman et al., 2003). Thus, it was possible that p38 kinases blocked or reversed cells in early prophase by inhibiting cyclin A–dependent kinases, perhaps by inactivating the Cdc25 phosphatases. If inactivation of cyclin A–Cdk complexes was required for the antephase checkpoint, we reasoned that cyclin A in a complex with a mutant form of Cdk that could not be inactivated by phosphorylation should overcome the checkpoint. In support of this reasoning, when we injected cells with cyclin A and followed by time-lapse DIC and fluorescence microscopy at 3-min intervals as it returned to antephase. The cell is representative of four cells in seven experiments. Bar, 10 μm. Videos are available at http://www.jcb.org/cgi/content/full/jcb.200401139/DC1.
Discussion

Here, we have shown that the Chfr protein is an important component of the antephase checkpoint in mammalian cells and that the p38 stress kinases appear to be downstream effectors of the checkpoint. As part of the checkpoint mechanism, Chfr requires its ubiquitin ligase activity, but its substrates do not need to be degraded by the proteasome. This is the first direct demonstration of a link between Chfr and the antephase checkpoint; originally Chfr was reported to be required for a checkpoint that prevented entry to metaphase after cyclin B1-Cdk1 is activated (Scolnick and Halazonetis, 2000). However, our evidence indicates that Chfr is required for the antephase checkpoint, and, in agreement with Rieder and Cole (1998), we find that cells no longer respond to the antephase checkpoint when the nucleoli begin to breakdown, which is the time when significant amounts of active cyclin B1 first appear in the cell and move into the nucleus (Jackman et al., 2003). We also find that active cyclin A–Cdk complexes can override the checkpoint, indicating that cyclin A–Cdds may be targets of the checkpoint.

At present, we are unable to explain exactly how Chfr acts in the checkpoint. Clearly, Chfr must be acting as an ubiquitin ligase because wild-type Chfr, but not a RING finger mutant, is able to restore the antephase checkpoint in U2OS cells. Moreover, methylated ubiquitin, which blocks polyubiquitylation, abolishes the checkpoint. In contrast to X. laevis extracts, in mammalian cells Chfr does not need to target its substrates for proteasome-dependent degradation to block progress into mitosis because the checkpoint is unaffected by proteasome inhibitors. Thus, we believe that Chfr acts in a signaling pathway by generating ubiquitin chains that are conjugated through K63. In support of this belief, we find that Chfr binds to Ubc13 in a yeast 2 hybrid assay, and in collaboration with J. Chen (personal communication), we have found that Chfr requires Ubc13 to autoubiquitylate (unpublished data). This finding is in agreement with the recent report that Chfr auto-ubiquitylates through K63 (Bothos et al., 2003). One intriguing possibility is that Chfr could activate the p38 stress kinase pathway by activating the TAK1 kinase. TAK1 is a MAP kinase kinase kinase in the p38 kinase pathway and can be activated by the TRAF6 ubiquitin ligase in response to interferon (Wang et al., 2001). Indeed, in a yeast 2 hybrid screen we have isolated the T6BP (TRAF6 binding protein) protein, which interacted with Chfr in a RING finger-dependent manner (unpublished data). T6BP is a protein that can interact with the TRAF6 protein (Ling and Goeddel, 2000). This finding raises the possibility that Chfr in combination with T6BP might be able to activate TAK1 in response to microtubule depolymerization. However, as yet, we have been unable biochemically to confirm this model.

Our evidence indicates that the p38 stress kinases are required to effect the antephase checkpoint and that they appear to act downstream or in parallel to Chfr. Chemical inhibitors of the p38α and β kinases abrogate the antephase checkpoint, and an active form of p38α, but not p38β or the related ERK2 kinase, is able to return early prophase cells to interphase. In animal cells, the p38 stress kinases have previously been implicated in two different late cell cycle checkpoints: in G2 phase (Bulavin et al., 2001) and in mitosis itself (Takenaka et al., 1998). Bulavin et al. (2001) showed that, in vitro, the p38 stress kinases are able to phosphorylate the Cdc25B phosphatase that can play a role in the initiation of mitosis, and that this may underlie the G2 arrest in response to UV damage (Bulavin et al., 2001). This mechanism may also be the means by which the p38 stress...
kinases are able to return prophase cells to interphase, and we show that cyclin A in a complex with a form of CDK2 that is independent of Cdc25 is able to overcome the antephase checkpoint. However, as yet, we have been unable to detect biochemically a change in the phosphorylation state of CDK2 bound to cyclin A when we activate the antephase checkpoint, nor when we activate the p38 kinases directly with anisomycin (Koop, L., personal communication; unpublished data), although this may simply reflect the practical difficulty in obtaining sufficient numbers of cells in late G2/early prophase.

Takenaka et al. (1998) reported that the p38 stress kinases are required to arrest mammalian cells in prometaphase when microtubules are destabilized with nocodazole. Thus, they implicated the p38 stress kinases as important components of the spindle assembly checkpoint. In fission yeast, the p38 stress kinase has been reported to be a component of a checkpoint required to arrest cells in mitosis when the spindle is misoriented (Gachet et al., 2001). However, we were unable to detect any change in the ability of cells to arrest in mitosis in response to nocodazole in the presence or absence of p38 kinase inhibitors. At present, we are unable to explain the apparent discrepancy in our results from those of Takenaka et al. (1998), although one difference in experimental protocols is that we assayed mitotic arrest by counting cells stained with Hoechst 33342, whereas Takenaka et al. (1998) assayed arrest more indirectly by measuring H1 kinase activity in cell lysates.

Materials and methods

Cell culture, synchronization, and drug treatments
HeLa and U2OS cells were cultured and synchronized as described previously (Jackman et al., 2003). Cell lines expressing inducible Chfr were cultured in DMEM plus 5% FBS, 5% newborn calf serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 0.292 mg/ml glutamine, 1% (vol/vol) G418 (GIBCO BRL), 0.25 mg/ml hygromycin B, and 0.5 mg/ml geneticin at 37°C/10% CO2. Ptk1 cells were cultured in Ham’s F-12 medium (GIBCO BRL), 10% FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 1 mM Na pyruvate, and 0.1% (vol/vol) Fungizone (GIBCO BRL) at 37°C/5% CO2. Colcemid was added to a final concentration of 15 μM, anisomycin to 50 ng/ml, SB203580 and SB202474 (Calbiochem) to 5 μM, H2O2 to 0.2 mM, MG-132 to 42 nM, MG-115 (Calbiochem) to 50 nM, and epoxomicin (Calbiochem) to 10 μM.

Protein expression, purification, and injection
Cyclin A–Cdk2 and cyclin A–Cdk2AF were expressed in and purified from Escherichia coli BL21 cells as described previously (Brown et al., 1999). Proteins were concentrated in injection buffer (12.5 mM Tris-HCl, pH 8.0, 200 mM NaCl, 2.5 mM DTT, and 1 mM EGTA) in a Vivaspin 5000 MW cut-off microconcentrator (Vivasience). Approximately 5% of the cell volume was injected into cells using a semiautomatic microinjector (Eppendorf) attached to a microscope (model DMIRBE; Leica). p38α, p38β, and p38δ were gifts of C. Smythe (University of Sheffield, Sheffield, UK). Ubiquitin (50 mg/ml) and methylated ubiquitin were purchased from Calbiochem.
Antephase checkpoint assay

For live cell assay, cells were cultured on 0.15-mm ∆T dishes (Biostechs) at 37°C, treated with the drugs colcemid (15 μM) or anisomycin (50 ng/ml), and followed by time-lapse DIC microscopy at 3-min intervals. Early prophase PtK1 cells were identified by the beginnings of chromosome condensation. U2OS cells were treated 11 h after release from a double thymidine block to increase the number of mitotic cells. When treated with 50 ng/ml anisomycin 30 min after the addition of the drug, the U2OS cultures were washed with fresh prewarmed medium six times and then followed by DIC microscopy. At least 200 cells were examined for each experiment, scored for nuclear envelope breakdown, and plotted on a graph.

Image acquisition

Images were acquired using a microscope and a 40× 1.0 NA or 63× 1.35 NA oil immersion objective as described previously (Karlsson and Pines, 1998) with the addition of a motorized XY stage (Prior Scientific) to visualize multiple fields of cells per time point. Images were taken with a cooled CCD camera (model Pentamax or Micromax; Roper Scientific) using IP Lab software (Scanalytics) and analyzed using ImageJ software (National Institutes of Health) before exporting to Adobe Photoshop for printing or Adobe Premiere to generate the Quicktime videos. The four-dimensional imaging of α-tubulin to generate DIC microscopy (model DeltaVision Spectris; Applied Precision) equipped with a 40× 1.35 NA lens (Olympus) and a cooled CCD camera (model CoolSnap HQ; Roper Scientific). Stacks of 29 z-images 0.4 μm apart were taken every 3 min, and the maximum intensity projections were combined using SoftWorx software for the images and videos in Fig. 5.

Immunofluorescence

To detect epitope-tagged Chfr, cells were fixed and permeabilized with 50: 50 vol/vol MeOH/Acetone and stained with anti-Xpress antibody (Invitrogen) at 1:2,000 dilution followed by an Alexa Fluor 488-labeled anti–mouse secondary antibody (Molecular Probes).

Fixed cell assay for prophase checkpoint

15 μM colcemid, 1 μg/ml anisomycin, 15 μM colcemid plus 5 μM SB203580, 15 μM colcemid plus 5 μM SB202474, or their carrier DMSO were directly added to the medium of cells growing on glass coverslips. At 0, 60, and 120 min after drug treatment, coverslips were removed from medium and fixed with 3% PFA in 1× PBS. Cultures were stained with Hoechst 33342. Coverslips were examined and mitotic cells were scored by epifluorescence using a microscope (model Optiphot; Nikon) equipped with a 20× 0.75 NA and a 40× 1.3 NA lens (Nikon).

Online supplemental material

A fixed cell assay showing that p38 kinases are required for the antephase checkpoint is shown in Fig. S1. Video 1 shows live cell imaging of the antephase checkpoint. Video 2 shows that ΔFAA Chfr abrogates the antephase checkpoint. Video 3 shows that wild-type Chfr rescues the antephase checkpoint in U2OS cells. Video 4 shows that the Ring finger mutant of Chfr fails to rescue an antephase checkpoint defect. Video 5 shows that anisomycin can activate the antephase checkpoint. Video 6 shows live cell imaging of HeLa cells stably expressing α-tubulin-EYFP. Video 7 shows that anisomycin reverses the accumulation of α-tubulin on centrosomes. Online supplemental material is available at http://www.jcb.org/cgi/content/full/jcb.200401139/DC1.

We are very grateful to Catherine Lindon who made the observation that the mitotic index decreased in anisomycin-treated cells and to Conly Rieder for advice, discussions, and communicating unpublished results. Many thanks to Cecile Pickett, Carl Smythe, and Angel Nebreda for help and advice, and to James Chen for ongoing collaborative efforts. This work was supported by a Japan Science Promotion Society fellowship to T. Matsusaka, the Association for International Cancer Research, and programme grant C29/A1782 to J. Pines from Cancer Research UK.

Submitted: 28 January 2004
Accepted: 6 July 2004

References


